What was Intuitive Surgical's revenue in Q2 2026?

Revenue was $2.89 billion, up 18.5% year over year.

Why did ISRG stock drop despite beating estimates?

The stock fell due to reports of declining overall surgery volumes and a Class II recall of certain da Vinci surgical components.

What was Intuitive Surgical's non-GAAP EPS?

Non-GAAP EPS was $2.80, beating analyst consensus by 11.9%.

What is the da Vinci medical recall?

It is a Class II recall of certain da Vinci surgical system components, raising product safety concerns.

Intuitive Surgical (ISRG) Beats Q2 2026 Sales Estimates But Stock Falls

Intuitive Surgical (ISRG) reported Q2 2026 revenue of $2.89 billion, up 18.5% year over year, beating Wall Street expectations. Non-GAAP EPS of $2.80 also exceeded consensus by 11.9%. Despite the beat, shares declined amid reports of lower overall surgery volumes and a Class II recall of certain da Vinci surgical components.

Medical technology company Intuitive Surgical (NASDAQ:ISRG) reported Q2 2026 results that surpassed Wall Street expectations, with revenue reaching $2.89 billion, an 18.5% increase year over year. Non-GAAP earnings per share came in at $2.80, beating analyst consensus by 11.9%. Despite the strong performance, ISRG shares fell in recent trading.

Key Financial Results

Metric	Value	YoY Change
Revenue	$2.89B	+18.5%
Non-GAAP EPS	$2.80	+11.9% above consensus
Net Income	Not disclosed	-

Highlights from the Release

The company attributed its strong performance to increased global adoption of da Vinci surgical systems but noted challenges in overall surgery volumes.

Guidance

Intuitive Surgical did not provide specific quarterly guidance but expects continued growth in robotic surgery demand.

Impact on Stock

Despite the earnings beat, the stock declined due to reports of a broader slowdown in surgery volumes from major healthcare providers and a Class II recall of certain da Vinci surgical components.

What This Means for Investors

The results demonstrate strong demand for Intuitive's products, but concerns over surgery volumes and the recall may create short-term volatility. Investors should monitor developments regarding the da Vinci recall and overall surgical trends.